Evidence map›Paper›PMID 25543051›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2015

Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.

Ashwini S Phadnis-Moghe, Robert B Crawford, Norbert E Kaminski

Open access · bronzeAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ashwini S Phadnis-Moghe*Genetics Program, Center for Integrative Toxicology and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, 48824 *Genetics Program, Center for Integrative Toxicology and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, 48824.
Robert B Crawford*Genetics Program, Center for Integrative Toxicology and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, 48824 *Genetics Program, Center for Integrative Toxicology and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, 48824.
Norbert E Kaminski*Genetics Program, Center for Integrative Toxicology and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, 48824 *Genetics Program, Center for Integrative Toxicology and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, 48824 kamins11@msu.edu.
Michigan State University · US

Funding

VOLATILE ORGANIC CONTAMINANTS--QUANTIFYING THEIR MOVEMENT IN THE UNSATURATED ZONEP42ES004911 · NIEHS · MICHIGAN STATE UNIVERSITY · PI Timothy R. Zacharewski · 1989 to 2026
$64.9M
TOXIC EFFECTS OF TCDD ON B CELLSR01ES002520 · NIEHS · VIRGINIA COMMONWEALTH UNIVERSITY · PI KAMINSKI, NORBERT E · 1986 to 2016
$4.2M
NIEHS NIH HHS P42 ES004911NIEHS NIH HHS P42 ES04911NIEHS NIH HHS R01 ES002520
6 · The paper itself

Abstract

The environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) produces marked suppression of the primary humoral immune response in virtually every animal species evaluated thus far. In addition, epidemiological studies performed in areas of dioxin contamination have identified an association between TCDD exposure and an increased incidence of non-Hodgkin's lymphoma (NHL). Recent studies using an in vitro CD40 ligand model of human B cell differentiation have shown that TCDD impairs both B cell activation and differentiation. The present study extends these findings by identifying B cell lymphoma-6 [BCL-6] as a putative cellular target for deregulation by TCDD, which may contribute to suppression of B cell function as well as NHL. BCL-6 is a multifunctional transcriptional repressor frequently mutated in NHLs and known to regulate critical events of B cell activation and differentiation. In the presence of TCDD, BCL-6 protein levels were elevated and concurrently the same population of cells with high BCL-6 levels showed decreased CD80 and CD69 expression indicative of impaired cellular activation. The elevated BCL-6 levels resulted in a concomitant increase in BCL-6 DNA binding activity at its cognate binding site within an enhancer region for CD80. Furthermore, a small molecule inhibitor of BCL-6 activity reversed TCDD-mediated suppression of CD80 expression in human B cells. In the presence of a low-affinity ligand of the aryl hydrocarbon receptor (AHR), suppression of B cell activation and altered BCL-6 regulation were not observed. These results provide new mechanistic insights into the role of BCL-6 in the suppression of human B cell activation by TCDD.

Indexed as

AnimalsAntigens, CDAntigens, Differentiation, T-LymphocyteB7-1 AntigenBasic Helix-Loop-Helix ProteinsBinding SitesB-LymphocytesCD40 LigandCD69 AntigensCell LineDNA-Binding ProteinsEnhancer Elements, GeneticEnvironmental PollutantsHumansImmunosuppressive AgentsLectins, C-TypeAHR protein, humanAntigens, CDAntigens, Differentiation, T-LymphocyteB7-1 AntigenBasic Helix-Loop-Helix ProteinsBCL6 protein, humanCD40 LigandCD69 AntigensDNA-Binding ProteinsEnvironmental PollutantsImmunosuppressive AgentsLectins, C-TypePolychlorinated DibenzodioxinsProto-Oncogene Proteins c-bcl-6Receptors, Aryl HydrocarbonAHR pathwayimmunotoxicityimpaired B cell activationTCDD

Identifiers

PMID25543051
PMCPMC4349138
OpenAlexW2023474157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.